K2 Principal Fund L.P. Sells 11,441 Shares of Catalent, Inc. (NYSE:CTLT)

K2 Principal Fund L.P. reduced its stake in Catalent, Inc. (NYSE:CTLT - Free Report) by 34.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,607 shares of the company's stock after selling 11,441 shares during the period. K2 Principal Fund L.P.'s holdings in Catalent were worth $1,309,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Athos Capital Ltd acquired a new position in shares of Catalent during the 3rd quarter worth about $6,009,000. Dynamic Technology Lab Private Ltd bought a new stake in Catalent in the third quarter valued at approximately $1,131,000. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Catalent by 3.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company's stock worth $24,550,000 after purchasing an additional 14,373 shares in the last quarter. Quest Partners LLC raised its stake in Catalent by 289.8% during the 3rd quarter. Quest Partners LLC now owns 49,300 shares of the company's stock worth $2,986,000 after buying an additional 36,652 shares during the period. Finally, Quarry LP bought a new position in Catalent during the third quarter worth about $4,482,000.

Analyst Upgrades and Downgrades

Several research firms recently commented on CTLT. StockNews.com raised shares of Catalent from a "sell" rating to a "hold" rating in a research report on Monday, December 2nd. Baird R W downgraded shares of Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Robert W. Baird restated a "neutral" rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Finally, William Blair restated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Eight research analysts have rated the stock with a hold rating, According to data from MarketBeat, Catalent has an average rating of "Hold" and a consensus target price of $63.40.

Catalent Stock Down 0.5 %

Shares of CTLT traded down $0.29 during trading hours on Friday, reaching $61.83. The stock had a trading volume of 2,714,572 shares, compared to its average volume of 1,845,382. The firm has a 50-day simple moving average of $60.07 and a 200 day simple moving average of $58.74. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $62.20. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The company has a market capitalization of $11.22 billion, a price-to-earnings ratio of -27.36, a P/E/G ratio of 2.46 and a beta of 1.15.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the business earned ($0.10) earnings per share. The firm's quarterly revenue was up 4.2% compared to the same quarter last year. Equities research analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company's stock, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the company's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares of the company's stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 over the last ninety days. 0.31% of the stock is currently owned by insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.